| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 70.66 | 59.9% | 10.9% |
| Total Income | 70.66 | 59.9% | 10.9% |
| Expenditure | 81.67 | 23.2% | 56.1% |
| PBT | -17.27 | 37.4% | 445.4% |
| Net Profit | -17.27 | 37.4% | 445.4% |
| OPM | -15.58% | 34.37pp | 33.48pp |
| NPM | -24.44% | 38.00pp | 32.28pp |
| EPS | -0.46 | 37.8% | 428.6% |
Harrow Announces Second Quarter 2026 Financial Results
11 Aug 2026 · 11 Aug, 1:49 am
Summary
Harrow, Inc. announced its financial results for the second quarter of 2026, reporting revenue of $70.7 million, a significant 60% increase sequentially and an 11% increase year over year. Key products like VEVYE® and IHEEZO® showed strong performance, with VEVYE® revenue up 40% sequentially and IHEEZO® achieving record unit demand. The company reiterated its full-year 2026 guidance for revenue and Adjusted EBITDA, signaling confidence in its growth trajectory. Management highlighted the strategic acquisition of TYRVAYA® and the launch of BYOOVIZ® as key developments positioning the company for accelerated growth in the second half of the year.
Key Highlights
- 1
Quarterly revenue reached $70.7 million, marking a 60% sequential increase and an 11% year-over-year rise.
- 2
VEVYE® delivered $29.4 million in quarterly revenue, growing approximately 40% sequentially and 58% year over year, with continued growth in prescriptions, prescribers, and market share.
- 3
IHEEZO® achieved quarterly revenue of $15.6 million and recorded its strongest quarter for unit demand to date, with unit demand increasing 44% sequentially and 34% year over year.
- 4
TRIESENCE® delivered record quarterly unit demand, increasing 39% sequentially and 162% year over year.
- 5
The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA.
- 6
Harrow announced the acquisition of TYRVAYA®, which is expected to close during the second half of 2026 and contribute modestly to 2026 revenue.
- 7
Cash and cash equivalents stood at $83.9 million as of June 30, 2026.
Management Comments
Mark L. Baum
We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability. Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ®, advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1. IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth – reinforcing our conviction that physician demand continues to strengthen across our portfolio. As we enter the second half of the year, the business looks fundamentally different than it did just a few months ago: IHEEZO’s pricing improvements are now in effect, IHEEZO’s channel inventories have normalized, VEVYE’s updated business rules have been fully implemented, BYOOVIZ has launched, and TYRVAYA is expected to join our portfolio later this year. Our commercial organization, which already expanded this year (and is now helping to fueling our growth), will increase further with the addition of experienced eye care sales professionals from Viatris. Together, these steps position us to convert the demand we’ve built into meaningful revenue growth and profitability. I believe Harrow has reached an important inflection point. The heavy lifting required to position the business for accelerated growth has largely been completed. The table is set. Now it’s about execution. Based on what we’re seeing across the business today, I remain confident in our ability to deliver our full-year guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA.
Informational and educational content only. Not investment advice.